PPT-Simplification to Efavirenz-Tenofovir DF-Emtricitabine

ADONE Trial Simplification to EfavirenzTenofovir DFEmtricitabine ADONE Study Design Source Airoldi M et al Patient Prefer Adherence 2010411525 Study Design ADONE Study Background. Lexical Simplification. A subtask of text simplification. Replacing words or short phrases by . simpler variants. in a context aware fashion. Motivation. To reach out to wider range of readers having limited vocabulary. GENERIC ARVs. Tim Horn. Treatment Action Group. tim.horn@treatmentactiongroup.org. Federal AIDS Policy Partnership Meeting. December 2014. Patents and Exclusivity 101 . Myriad Policies. Patents issued >1996 have term of 20 years. By Scott . Kominers. And. Lukens Orthwein. Computational Complexity. Eliminating “Bad” . Equilibria. Unsophisticated Buyers. Lazy Participants. Why Simplify?. Milgrom’s. Simplification . Thm. .. Cody Dunne and Ben Shneiderman. {cdunne, ben}@. cs.umd.edu. 30. th. . Annual . Human-Computer Interaction Lab Symposium, May 22–23, 2013. College Park, . MD. Who Uses Network Analysis. Network Analysis is Hard. Kevin L. Ard, MD, MPH. October 20, 2016. Learning objectives. Summarize the indications for and management of pre- and post-exposure prophylaxis. Understand clinical uncertainties in pre-exposure prophylaxis management. Treatment-naïve Patients . Clinical Instructor, Harvard Medical School. Director of Research, CRI New England. Vice Chair, INSIGHT Scientific Steering Committee. Boston, USA . Calvin Cohen, MD, MSc. Access and Rational Use. Blood, Radiological and Pharmaceutical Services. Regulatory System Strengthening. Systems approach/ Across all technologies. Contemplate the specificities off specific technologies. of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Nithya Srinivas. 1. , John Fallon. 1. , Craig Sykes. 1. , Nicole White. 1. , Amanda Schauer. 1. , Lou Adamson. 2. , Michelle Matthews. 1. , Paul Luciw. 2. , Phil Smith. 1. , Angela DM Kashuba. 1. 1. University of North Carolina at Chapel Hill, Chapel Hill, United States, . Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Text Simplification David Kauchak CS159 – Spring 2019 Collaborators: Will Coster , Dan Feblowitz and Gondy Leroy Admin Final projects Wednesday’s lecture Text simplification Any intelligent fool can make things bigger, more complex, and more violent. It takes a touch of genius and a lot of courage to move in the opposite direction. . SSAT-029 STUDY . Switch to Etravirine from Efavirenz Due to CNS Toxicity . SSAT-029: Design. Source: Waters L, et al. . AIDS. 2011;25:65-71.. Immediate. . Switch Arm. Etravirine. + 2NRTI. (n = 20). FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. SWEET Trial . Switch to Efavirenz + TDF-FTC . SWEET: Study Design. Source: Fisher M, et al. . J Acquir Immune Defic Syndr. 2009;51:562-8.. Background. : Randomized, . controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed .